Revolution Medicines, Inc. (RVMD)

39.19 +0.37 (+0.95%) At close: 04:00PM EDT

Revolution Medicines, Inc.

700 Saginaw Drive
Redwood City, CA 94063
United States
650 481 6801
https://www.revmed.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 378

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Mark A. Goldsmith Ph.D.	CEO, President & Chairman	1.12M	2.85M	1962
Mr. Jack Anders	Chief Financial Officer	665.28k	1.02M	1977
Ms. Margaret A. Horn J.D.	Chief Operating Officer	811.08k	1.68M	1963
Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.	President of Research & Development	812.17k	N/A	1961
Ms. Xiaolin Wang	Executive Vice President of Development	633.74k	N/A	1971
Dr. Martin D. Burke M.D., Ph.D.	Co-Founder & Chairman of Scientific Advisory Board	N/A	N/A	N/A
Dr. Michael A. Fischbach Ph.D.	Academic Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1981
Dr. Kevan M. Shokat Ph.D.	Academic Co-Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Mr. Walter Reiher Ph.D.	Chief Information Officer	N/A	N/A	N/A
Ms. Jan Smith Ph.D.	Chief Scientific Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Corporate governance

Revolution Medicines, Inc.’s ISS governance QualityScore as of 1 May 2024 is 7. The pillar scores are Audit: 3; Board: 8; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.